ClinicalTrials.gg
WithdrawnNCT05564338Updated Jun 7, 2023

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

A Phase 3 interventional study of Sitravatinib and Tislelizumab in Hepatocellular Carcinoma, sponsored by BeiGene. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-07.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern or the request from any health authority worldwide.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tislelizumab in Carcinoma, Hepatocellular — 23 open to participants now, 25 under way, 2 of them phase 3. tislelizumab · Carcinoma, Hepatocellular.

Enrollment
43rd of 43
0 · median 40
Started
2023
with 5 others
Phase 3
4 of 43
2 open now
Registered
22nd of 43
by date
Lead sponsor
5 of 43
BeiGene

Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, this one is the 43rd largest by enrollment, is one of 6 that started in 2023, is one of 4 in phase 3, and was the 22nd registered.

Carcinoma, Hepatocellular

3,650 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 43 studies testing tislelizumab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tislelizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of sitravatinib plus tislelizumab or placebo plus tislelizumab versus placebo. The study will also compare the recurrence-free survival (RFS) in participants with hepatocellular carcinoma (HCC) who are at high risk of recurrence after surgical resection.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • hepatocellular carcinoma
  • sitravatinib
  • tislelizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant with a first diagnosis of HCC must have undergone a curative-intent resection within 4 to 12 weeks before randomization and have a documented histological confirmation of HCC diagnosis and negative surgical margins (R0 resection) of the resected tumor
  2. Participant must have tumor-free status as assessed by the investigator and have fully recovered from surgical resection before randomization
  3. Participant must have no extrahepatic HCC
  4. Performance Status ≤ 1
  5. Participant who has undergone surgical resection and is defined as having a high risk of HCC recurrence

Key Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology
  2. Evidence of residual, recurrent, or disease of HCC before randomization
  3. Major macrovascular (gross vascular) invasion of the portal vein (Vp3 or Vp4) or any grade of macrovascular invasion in the hepatic vein or inferior vena cava
  4. Untreated chronic (HBV) or chronic HBV carriers with HBV DNA ≥ 2000 IU/mL at Screening
  5. Untreated or incompletely treated esophageal or gastric varices with bleeding or high risk of bleeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment Arm A: sitravatinib + tislelizumab

    sitravatinib once daily and tislelizumab once every 6 weeks, for up to 17 cycles (approximately 2 years)

    Drug: Sitravatinib · Drug: Tislelizumab

  • Experimental
    Treatment Arm B: Placebo + tislelizumab

    sitravatinib-matching placebo once daily and tislelizumab once every 6 weeks, for up to 17 cycles (approximately 2 years)

    Drug: Tislelizumab · Drug: sitravatinib-matching placebo

  • Experimental
    Treatment Arm C:Sitravatinib + Placebo

    sitravatinib once daily and tislelizumab-matching placebo once every 6 weeks, for up to 17 cycles (approximately 2 years)

    Drug: Sitravatinib · Drug: tislelizumab-matching placebo

  • Experimental
    Treatment Arm D: Matching Placebo

    sitravatinib-matching placebo once daily and tislelizumab-matching placebo once every 6 weeks, for up to 17 cycles (approximately 2 years)

    Drug: sitravatinib-matching placebo · Drug: tislelizumab-matching placebo

Interventions

  • Administered orally

  • Administered intravenously

  • Drugsitravatinib-matching placebo

    administered orally

  • Drugtislelizumab-matching placebo

    administered intravenously

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival (RFS) as assessed by the investigator between Arm A and Arm D

    RFS is defined as the time from the date of randomization until the date of the first documented occurrence of intrahepatic or extrahepatic hepatocellular carcinoma (HCC) as assessed by the investigator, or death from any cause, whichever occurs first.

    Time frame: Up to 2 Years

  2. Recurrence-free survival (RFS) as assessed by the investigator between Arm B and Arm D

    defined as the time from the date of randomization until the date of the first documented occurrence of intrahepatic or extrahepatic hepatocellular carcinoma as assessed by the investigator, or death from any cause, whichever occurs first.

    Time frame: Up to 2 Years

Secondary outcomes

  1. Arm A and Arm B: Recurrence-free survival (RFS)

    defined as the time from the date of randomization until the date of the first documented occurrence of intrahepatic or extrahepatic hepatocellular carcinoma as assessed by the investigator, or death from any cause, whichever occurs first.

    Time frame: Up to 2 Years

  2. Arm A and Arm C: Recurrence-free survival (RFS)

    defined as the time from the date of randomization until the date of the first documented occurrence of intrahepatic or extrahepatic hepatocellular carcinoma as assessed by the investigator, or death from any cause, whichever occurs first.

    Time frame: Up to 2 Years

  3. Arm A and Arm D: overall survival (OS)

    defined as the time from the date of randomization until the date of death due to any cause

    Time frame: Up to 5 Years

  4. Arm B and Arm D: overall survival (OS)

    defined as the time from the date of randomization until the date of death due to any cause

    Time frame: Up to 5 Years

  5. Arm A and Arm B: overall survival (OS)

    defined as the time from the date of randomization until the date of death due to any cause

    Time frame: Up to 5 Years

  6. Arm A and Arm C: overall survival (OS)

    defined as the time from the date of randomization until the date of death due to any cause

    Time frame: Up to 5 Years

  7. Arm A and Arm D: time to extrahepatic spread (EHS) as assessed by the investigator

    defined as the time from the date of randomization until the date of the first documented occurrence of extrahepatic HCC

    Time frame: Up to 2 Years

  8. Arm B and Arm D: time to extrahepatic spread (EHS) as assessed by the investigator

    defined as the time from the date of randomization until the date of the first documented occurrence of extrahepatic HCC

    Time frame: Up to 2 Years

  9. Arm A and Arm B: time to extrahepatic spread (EHS) as assessed by the investigator

    defined as the time from the date of randomization until the date of the first documented occurrence of extrahepatic HCC

    Time frame: Up to 2 Years

  10. Arm A and Arm C: time to extrahepatic spread (EHS) as assessed by the investigator

    defined as the time from the date of randomization until the date of the first documented occurrence of extrahepatic HCC

    Time frame: Up to 2 Years

  11. Number of participants with adverse events (AEs)

    Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0, vital signs, and clinical laboratory test results in the Safety Analysis Set

    Time frame: Up to 5 Years

  12. Participants Reported Outcome as measured at Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its hepatocellular carcinoma cancer module QLQ-HCC18

    Quality of Life change with treatment. Scale scores are calculated by averaging items within scales and transforming average scores linearly. All of the scales range in score from 0 to 100

    Time frame: Up to 2 Years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Apr 2027, 46 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 3, 2022
StartEst.
Jun 30, 2023
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2028
Last update
Jun 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564338
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Jun 30, 2023 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Jun 7, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitravatinib · Tislelizumab

Start the discussion